United Kingdom · Series B startup
Funding summaryUpdated 26 Oct 2026
$79Mraised across 2 rounds since 2022, from 3 sources
Each circle is a round, placed by date and sized by amount. The line above is the running total.
Novartis Venture Fund
British Business Bank
Omega Funds
Brandon Capital
M/VENTURES
Criteria Bio VenturesReported by Firms' own news pages and 1 other
No investor was named in the report.
Shares issued, filed with Companies House (SH01); no report of this raise yet
NRG Therapeutics filed 3 raises, $12M in all. Filings say how much was sold and to how many investors; they never name the investors.
From NRG Therapeutics's own website: 1 founder, 2 on the team.
The busiest backers across the latest rounds. A filled square is a round they joined; a dark one, a round they led.
Missing a round, or an investor who was in one? Tell us.
NRG Therapeutics's investors include SV Health Investors' Dementia Discovery Fund (DDF), Novartis Venture Fund, British Business Bank, Omega Funds and Brandon Capital, and 2 more on record. SV Health Investors' Dementia Discovery Fund (DDF) led its latest round.
NRG Therapeutics has raised $79M across 2 rounds since 2022.
NRG Therapeutics's most recent round was a Series B of $68M in Sept 2025, led by SV Health Investors' Dementia Discovery Fund (DDF).
Its most recent round, $68M in Sept 2025, is also its largest on record.
NRG Therapeutics's first round on record, in Sept 2025, was backed by SV Health Investors' Dementia Discovery Fund (DDF), Novartis Venture Fund and British Business Bank and 4 others.
NRG Therapeutics's latest named round is a Series B, in Sept 2025.
NRG Therapeutics is based in the United Kingdom.
SV Health Investors' Dementia Discovery Fund (DDF) led the Series B in 2025.
In the same sector, and raised in the last eighteen months.
Search every investor by what they have actually funded, then narrow to your stage and market. Free.
United Kingdom · 
